ABBV vs. JAZZ: AbbVie vs. Jazz Pharmaceuticals Stock Comparison
How do AbbVie (ABBV) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AbbVie (ABBV) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.
| Profile Item | ABBV | JAZZ |
|---|---|---|
| Name | AbbVie Inc. | Jazz Pharmaceuticals plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 514.92 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | January 2, 2013 | June 1, 2007 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| Total Return (1Y) | 37.33% | 84.44% |
| Total Return (3Y, Annualized) | 32.74% | 27.57% |
| Total Return (5Y, Annualized) | 24.73% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 25.65% | 38.74% |
| Beta (5Y) | 0.21 | 0.33 |
| Max Drawdown (5Y) | -21.92% | -42.03% |
| Avg. Volume (3M) | 4.76M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 1.29 | 2.07 |
| Sortino Ratio (1Y) | 2.02 | 4.14 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Jazz Pharmaceuticals (JAZZ) earns 5.05% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ABBV
- --
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
AbbVie (ABBV) at 15.67% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.67%
- Max
- 18.05%
- ABBV
- 15.67%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AbbVie (ABBV) at 39.59% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.59%
- Max
- 83.12%
- ABBV
- 39.59%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| ROE (TTM) | -- | 5.05% |
| ROA (TTM) | 10.74% | 6.92% |
| Net Margin (TTM) | 15.67% | 4.37% |
| Operating Margin (TTM) | 39.59% | 30.17% |
| Gross Margin (TTM) | 73.72% | 91.10% |
Growth
Revenue Growth
Both AbbVie (ABBV) at 8.57% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
AbbVie (ABBV) at -0.84% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 8.57% | 4.88% |
| Revenue Growth (3Y CAGR) | 1.75% | 5.26% |
| EPS Growth (YoY) | -0.84% | -167.51% |
| EPS Growth (3Y CAGR) | -29.03% | -- |
Financial Strength
Current Ratio (MRQ)
Both AbbVie (ABBV) at 0.87 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ABBV
- 0.87
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Jazz Pharmaceuticals (JAZZ) carries debt-to-equity ratio of 1.35 against its industry range, while AbbVie (ABBV) reports no figure this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 1.82 |
| Debt / Equity (MRQ) | -- | 1.35 |
| Net Debt / EBITDA | 2.21 | 1.39 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.40%
- ABBV
- 2.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%).
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.35%
- ABBV
- 117.35%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 2.40% | 0.00% |
| Dividend Payout Ratio (TTM) | 117.35% | 0.00% |
Valuation
P/E Ratio (TTM)
Both AbbVie (ABBV) at 50.05 and Jazz Pharmaceuticals (JAZZ) at 69.46 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
50.05
- Max
- 85.34
- ABBV
- 50.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both AbbVie (ABBV) at 7.80 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.80
- Max
- 58.18
- Q3
- 25.77
- ABBV
- 7.80
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 3.59, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-112.34
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- ABBV
- -112.34
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ABBV | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 50.05 | 69.46 |
| P/S Ratio (TTM) | 7.80 | 3.19 |
| P/B Ratio (MRQ) | -112.34 | 3.59 |
| Free Cash Flow Yield (TTM) | 3.44% | 11.16% |